PharmaCyte Biotech, Inc.: Form 10-Q/A for the period ended Oct 31, 2015
Filed with the SEC on Jan 19, 2016 and accepted by EDGAR at Jan 19, 2016, 06:14 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2015-10-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2015-08-01 to 2015-10-31 | $0 | us-gaap:Revenues |
| Revenue | 6 months2015-05-01 to 2015-10-31 | $0 | us-gaap:Revenues |
| Cost of revenue | 3 months2015-08-01 to 2015-10-31 | $0 | us-gaap:CostOfRevenue |
| Cost of revenue | 6 months2015-05-01 to 2015-10-31 | $0 | us-gaap:CostOfRevenue |
| Gross profit | 3 months2015-08-01 to 2015-10-31 | $0 | us-gaap:GrossProfit |
| Gross profit | 6 months2015-05-01 to 2015-10-31 | $0 | us-gaap:GrossProfit |
| Research and development | 3 months2015-08-01 to 2015-10-31 | $439.7k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2015-05-01 to 2015-10-31 | $595.4k | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2015-08-01 to 2015-10-31 | −$1.6m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2015-05-01 to 2015-10-31 | −$3.2m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2015-08-01 to 2015-10-31 | $194 | us-gaap:InterestExpense |
| Interest expense | 6 months2015-05-01 to 2015-10-31 | $826 | us-gaap:InterestExpense |
| Net income | 3 months2015-08-01 to 2015-10-31 | −$1.6m | us-gaap:NetIncomeLoss |
| Net income | 6 months2015-05-01 to 2015-10-31 | −$3.2m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2015-08-01 to 2015-10-31 | $0.00 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 6 months2015-05-01 to 2015-10-31 | $0.00 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 6 months2015-05-01 to 2015-10-31 | −$2.1m | us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations |
| Cash and equivalents | At period end2015-10-31 | $2.3m | us-gaap:Cash |
| Current assets | At period end2015-10-31 | $2.8m | us-gaap:AssetsCurrent |
| Total assets | At period end2015-10-31 | $8.0m | us-gaap:Assets |
| Current liabilities | At period end2015-10-31 | $1.1m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2015-10-31 | $1.1m | us-gaap:Liabilities |
| Shareholders' equity | At period end2015-10-31 | $6.9m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001019687-16-004860. Last ingested by Listed: Nov 14, 2026, 20:52 ET. Listed shows no prices and gives no investment advice.